← All trials
NCT05347147
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 18, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Apr 26, 2022
- Last posted
- Nov 22, 2022
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Invex Therapeutics Ltd.Lead sponsor
- Premier Research GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.